Yhdysvallat - englanti - NLM (National Library of Medicine)

marlex pharmaceuticals, inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use.

Yhdysvallat - englanti - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings. misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol should not be taken by anyone with a history of allergy to prostaglandins.

Yhdysvallat - englanti - NLM (National Library of Medicine)

micro labs limited - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol tablets are indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer.  misoprostol tablets has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids.  misoprostol tablets should be taken for the duration of nsaid therapy.  misoprostol tablets has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months’ duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings . misoprostol tablets should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol tablets should not be taken by anyone with a h

Yhdysvallat - englanti - NLM (National Library of Medicine)

genbiopro, inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings. misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol should not be taken by anyone with a history of allergy to prostaglandins.

Yhdysvallat - englanti - NLM (National Library of Medicine)

bryant ranch prepack - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings. misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol should not be taken by anyone with a history of allergy to prostaglandins.

Yhdysvallat - englanti - NLM (National Library of Medicine)

american health packaging - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings . misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol should not be taken by anyone with a history of allergy to prostaglandins.

Yhdysvallat - englanti - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - misoprostol is indicated for reducing the risk of nsaid (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking nsaids. misoprostol should be taken for the duration of nsaid therapy. misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. it had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with nsaid use. see boxed warnings. misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drugs (nsaids). misoprostol should not be taken by anyone with a history of allergy to prostaglandins.

Yhdysvallat - englanti - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - two 12-week, randomized, double-blind trials in osteoarthritic patients who had gastrointestinal symptoms but no ulcer on endoscopy while taking an nsaid compared the ability of 200 mcg of misoprostol tablets, 100 mcg of misoprostol tablets, and placebo to reduce the risk of gastric ulcer (gu) formation. patients were approximately equally divided between ibuprofen, piroxicam, and naproxen, and continued this treatment throughout the 12 weeks. the 200-mcg dose caused a marked, statistically significant reduction in gastric ulcers in both studies. the lower dose was somewhat less effective, with a significant result in only one of the studies. reduction of risk of gastric ulcers induced by ibuprofen, piroxicam, or naproxen                       [no. of patients with ulcer(s) (%)] in these trials there were no significant differences between misoprostol tablets and placebo in relief of day or night abdominal pain. no effect of misoprostol tablets in reducing the risk of duodenal ulcers was demonstrated, but rel

Yhdysvallat - englanti - NLM (National Library of Medicine)

direct rx - misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57), diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 75 mg - carefully consider the potential benefits and risks of diclofenac sodium/misoprostol tablets and other treatment options before deciding to use diclofenac sodium/misoprostol tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). diclofenac sodium/misoprostol tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. see warnings, gastrointestinal effects - risk of ulceration, bleeding, and perforation for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications. see boxed contraindications and warnings related to misoprostol. diclofenac sodium/misoprostol tablets should not be taken by pregnant women. diclofenac sodium/misoprostol tablets are contraindicated in patients with hypersensitivity

Yhdysvallat - englanti - NLM (National Library of Medicine)

proficient rx lp - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions (5.2)] . diclofenac sodium and misoprostol delayed-release tablets are contraindicated in the following patients: risk summary diclofenac sodium and misoprostol delayed-release tablets are contraindicated in pregnant women [see contraindications (4)] . there are no adequate and well-controlled studies of diclofenac sodium and misoprostol delayed-release tablets in pregnant women; however, there is information available about the active drug components of diclofenac sodium and misoprostol delayed-release tablets, diclofenac sodium and misoprostol. administration of misoprostol to pregnant women can cause abort